$Mind Medicine (MNMD.US)$ all work force buisness owner operators should invest into this companies products. this could not only benifit people with the disorders outlined in their descriptions but think about our work force in general I know for the agency I work for we have call ins all the time and generally speaking it's almost always the same people it isn't just my agency but national, jobs every wherewould benifit. so this company could help everyone every where! This company will ris...
$Mind Medicine(MNMD.US)$Mind Medicine Presents New Studies At ISPOR 2024 Showing Growing Burden And Impact Of Generalized Anxiety Disorder In The U.S. Benzinga· just GAD Diagnosis Increases Healthcare Costs and Decreases Work Productivity and Health-Related Quality of Life- -People with Undiagnosed GAD Incur Even Higher Total Healthcare Costs than those Diagnosed with GAD- -Comprehensive Analyses of GAD Disease Burden in the US Conducted by MindMed; Company is Investigating New Treatments...
$Mind Medicine(MNMD.US)$ NEWS MindMed Reports First Quarter 2024 Financial Results and Business Updates MindMed received Breakthrough Therapy Designation (BTD) from the FDA for MM120 in the treatment of GAD in adults, after positive Phase 2b results showing statistically significant activity through 12 weeks. The Company has a strong financial position with $252.3 million in cash and cash equivalents as of March 31, 2024, sufficient to fund operations into 2026. MindMed is on track to begin its ...
The FDA breakthrough status and positive trial results for MM120 are seen as significant developments for Mind Medicine, leading to a surge in its stock price and an increased price target from Roth Capital Partners.
Mind Medicine股票讨论区
Benzinga· just
GAD Diagnosis Increases Healthcare Costs and Decreases Work Productivity and Health-Related Quality of Life-
-People with Undiagnosed GAD Incur Even Higher Total Healthcare Costs than those Diagnosed with GAD-
-Comprehensive Analyses of GAD Disease Burden in the US Conducted by MindMed; Company is Investigating New Treatments...
NEWS
MindMed Reports First Quarter 2024 Financial Results and Business Updates
MindMed received Breakthrough Therapy Designation (BTD) from the FDA for MM120 in the treatment of GAD in adults, after positive Phase 2b results showing statistically significant activity through 12 weeks.
The Company has a strong financial position with $252.3 million in cash and cash equivalents as of March 31, 2024, sufficient to fund operations into 2026.
MindMed is on track to begin its ...
bought position at 2.60🧠 said it was going to 17.0+ by end of the year. Its half way 💎
now my $Cybin(CYBN.US)$ and $ATAI Life Sciences(ATAI.US)$ are setting up for take off also. 🚀
Women's Day I hope for flowers 🌺
暂无评论